Clinical Effect of Panfoxol of Otolaryngological Diseases of Upper Respiratory Tract Infection: A Multicenter Retrospective Observational Study

• Status: Completed
• Trial end date: 2022-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Patients with otolaryngological diseases caused by upper respiratory tract infections, including allergic rhinitis, chronic rhinosinusitis, secretory otitis media, and oblate gland hypertrophy, were treated with all drugs from Sun Yat-sen Memorial Hospital of Sun Yat-sen University, the First Affiliated Hospital of Sun Yat-sen University, Guangdong Provincial People's Hospital, and Guangdong Provincial Hospital of Traditional Chinese Medicine from January 2021 to December 2022. According to the treatment methods, the patients were divided into panfosol + conventional treatment group and conventional treatment group for multicenter retrospective analysis.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Criteria

Inclusion Criteria:

1. those who were diagnosed as ear, nose and throat diseases caused by upper respiratory tract infection, such as allergic rhinitis, chronic rhinosinusitis, secretory otitis media, and oblate gland hypertrophy

2. Complete clinical data were available at least once both before and after treatment

Exclusion Criteria:

1. Patients who are allergic to the ingredient panfosol

2. Autoimmune disease

3. Acute intestinal infection

4. Children younger than 1 year old

5. Patients diagnosed with nasopharyngeal carcinoma and other space-occupying diseases by imaging examination

6. Basic information is incomplete